Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung.

By applying the highly sensitive PEA, reliable protein profiles could be determined in microliter amounts of plasma. We further identified proteins that demonstrated different plasma concentration in defined disease groups and developed a signature that holds potential to be included in a screening assay for early lung cancer detection.